FTC Ends Probe Into Allergan’s Practices

Allergan Inc., the maker of Botox anti-wrinkle treatments, said the Federal Trade Commission had closed its investigation into whether the company hindered generic drug makers from making copies of its Acular eye drug.

Irvine-based Allergan said the decision followed a U.S. District Court ruling in December that concluded the patent covering Acular was valid and enforceable, the company said.